Sign In
Last checked at 
13 Aug 2020 07:00
IXICO plc
("IXICO" or the "Company")
Investor Presentation
IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it will provide a live presentation presented by CEO, Giulio Cerroni and CFO, Grant Nash, on Tuesday 25 August at 1.30pm.
The Company is committed to providing an opportunity for all existing and potential investors to hear directly from management, providing an update on the business and current trading. The presentation will be hosted through the digital platform Investor Meet Company. Investors can sign up to Investor Meet Company for free and add to meet IXICO plc via the following link:
https://www.investormeetcompany.com/ixico-plc/register-investor
Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards. No new price sensitive information will be disclosed, and a PDF of the presentation will be uploaded to the Company's website.
For further information please contact:
IXICO plc | +44 (0)20 3763 7498 | |
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
| |
|
| |
Cenkos Securities PLC (Nominated adviser and sole broker) | +44 (0)20 7397 8900 | |
Giles Balleny / Max Gould (Corporate Finance) |
| |
Michael F Johnson / Russell Kerr (Sales) |
| |
|
| |
Walbrook PR Ltd | Tel: 020 7933 8780 or IXICO@walbrookpr.com | |
Paul McManus / Lianne Cawthorne / Alice Woodings | Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 | |
|
| |
About IXICO
IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience.
Our goal is to be a leading proponent in the use of AI in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.
More information is available on www.IXICO.com
Follow the stocks
